Eco Wave Power's CEO Inna Braverman will participate in the Israel U.S. Climate Meetings Cafe on September 23, 2026, during Climate Week NYC. The event connects Israeli climate tech firms with U.S. investors and partners to promote renewable energy solutions. Eco Wave Power, known for its onshore wave energy technology, aims to expand its global presence and discuss commercialization and strategic partnerships. This participation follows Braverman's involvement in Climate Week panels on ocean-climate action and AI-driven sustainability solutions, highlighting the company's role in advancing renewable energy and digital infrastructure integration.
Eco Wave Power's participation in the Israel Economic Mission and Climate Tech Investor Event offers context on the energy sector's current market activity. Of 30 priced Energy-sector US stocks tradable on Pluang, 10 rose and 18 fell today. Notable movers include Valero Energy Corporation at USD 400.20 with a 1-day change of -0.76%, Devon Energy Corp at USD 48.08 with a 1-day change of -0.74%, and Occidental Petroleum Corporation at USD 58.93 with a 1-day change of -0.72%, as of Sep 17, 2026 19:12 WIB.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
